TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21705173

Group type: EXPERIMENTAL
Intervention: OMS103HP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (lactated Ringer's)
Number of subjects: 0
Study: 19148110

Group type: EXPERIMENTAL
Intervention: Intravenous digoxin immune Fab (DIF)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 26
Study: 16987678

Group type: EXPERIMENTAL
Intervention: neoadjuvant 5‐FU‐cisplatin based (13) or taxotere based (2 patients) chemoradiotherapy (45 Gy)
Number of subjects: 29

Group type: COMPARATOR
Intervention: no preoperative treatment
Number of subjects: 29
Study: 15334464

Group type: EXPERIMENTAL
Intervention: Manual measurement of interbone distance (IBD) and percentage of radiographic magnification (%Mag)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Automated measurement of JSW
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Manual measurement of JSW
Number of subjects: 15
Study: 10637198

Group type: EXPERIMENTAL
Intervention: Iodixanol (nonionic, iso-osmolar contrast medium)
Number of subjects: 1411

Group type: COMPARATOR
Intervention: Ioxaglate (ionic, low-osmolar contrast medium)
Number of subjects: 1411
Study: 9290688

Group type: EXPERIMENTAL
Intervention: Intraperitoneal heated chemotherapy (IPHC) with mitomycin (MMC) administered by perfusion at 40.5 degrees C
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study: 8305769

Group type: EXPERIMENTAL
Intervention: Heparin dosage adjustment using non-steady-state heparin concentrations (HCs)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group using only activated partial thromboplastin time (APTT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: HC group
Number of subjects: 34
Study: 3525055

Group type: EXPERIMENTAL
Intervention: Meal A (eggs, toasted wholemeal bread, orange juice, margarine, and milk)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Meal B (wheatflake biscuits, toasted wholemeal bread, milk, and margarine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Meal C (toasted muesli and skim milk)
Number of subjects: 8
Study: 31439506

Group type: EXPERIMENTAL
Intervention: Superextended or extended lymph node dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multimodal approaches including neoadjuvant or adjuvant chemotherapy
Number of subjects: 0
Study: 29068266

Group type: EXPERIMENTAL
Intervention: Tailored internet-supported cognitive behaviour therapy (ICBT) programme
Number of subjects: 66

Group type: COMPARATOR
Intervention: Weekly general support (Control)
Number of subjects: 66
Study: 26631904

Group type: EXPERIMENTAL
Intervention: Red wine extract of onion (RO) (250 mL for 10 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Red wine (RW) (250 mL for 10 weeks)
Number of subjects: 23
Study: 25085534

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Anticholinergic drugs (most frequently in haloperidol group)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Amisulpride, Olanzapine, Quetiapine, Ziprasidone
Number of subjects: 490
Study: 22506942

Group type: EXPERIMENTAL
Intervention: Voluntary HIV testing and brief counseling (VT/C)
Number of subjects: 1030
Study: 20647102

Group type: EXPERIMENTAL
Intervention: 17% EDTA for 1 minute (n = 30)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 7% maleic acid for 1 minute (n = 30)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.9% saline for 1 minute (n = 30)
Number of subjects: 45
Study: 17852312

Group type: EXPERIMENTAL
Intervention: Power-assisted functional electrical stimulation (FES) therapy, 30 sessions of approximately 60 min each, 6 days/week for 5 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Power-assisted functional electrical stimulation (FES) therapy
Number of subjects: 20
Study: 14728936

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (XRT-CT) with 5-FU 350 mg/m2/day and Leucovorin 20 mg/m2/day during the first and fifth weeks of XRT.
Number of subjects: 798

Group type: COMPARATOR
Intervention: Preoperative radiation (XRT) with 45 Gy, 25 fractions over 5 weeks.
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (XRT-CT) with 5-FU- LV.
Number of subjects: 798

Group type: COMPARATOR
Intervention: Preoperative radiation (XRT).
Number of subjects: 798
Study: 11502644

Group type: EXPERIMENTAL
Intervention: Tezosentan (20 mg/h)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tezosentan (50 mg/h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dobutamine (5 microg/kg/min)
Number of subjects: 14
Study: 9267580

Group type: EXPERIMENTAL
Intervention: Surgically assisted rapid maxillary expansion (SARME) with buccal corticotomies
Number of subjects: 42

Group type: COMPARATOR
Intervention: Orthopedic expansion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Orthodontic treatment without expansion
Number of subjects: 42
Study: 8492263

Group type: EXPERIMENTAL
Intervention: Dioralyte
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lucozade
Number of subjects: 9

Group type: COMPARATOR
Intervention: Potable water
Number of subjects: 9
Study: 3509066

Group type: EXPERIMENTAL
Intervention: 1-mg melatonin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5-mg melatonin
Number of subjects: 10
Study: 30971278

Group type: EXPERIMENTAL
Intervention: BCc1 nanomedicine (3000 mg for metastatic, 1500 mg for non-metastatic)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: BCc1 nanomedicine
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 27543500

Group type: EXPERIMENTAL
Intervention: 1 g of calcium as citrate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27816567

Group type: EXPERIMENTAL
Intervention: Bitopertin 10 mg (NightLyte)
Number of subjects: 1772

Group type: EXPERIMENTAL
Intervention: Bitopertin 20 mg (NightLyte)
Number of subjects: 1772

Group type: EXPERIMENTAL
Intervention: Bitopertin 10 mg (TwiLyte)
Number of subjects: 1772

Group type: EXPERIMENTAL
Intervention: Bitopertin 20 mg (TwiLyte)
Number of subjects: 1772

Group type: EXPERIMENTAL
Intervention: Bitopertin 5 mg (MoonLyte)
Number of subjects: 1772

Group type: EXPERIMENTAL
Intervention: Bitopertin 10 mg (MoonLyte)
Number of subjects: 1772

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1772
Study: 25163483

Group type: EXPERIMENTAL
Intervention: Multidisciplinary nutritional support
Number of subjects: 0
Study: 22493073

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 to 50 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Amiloride (10-20 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 to 10 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 19294950

Group type: EXPERIMENTAL
Intervention: REM sleep deprivation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SWS deprivation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Undisturbed sleep
Number of subjects: 12
Study: 17463213

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam 2 mg + oral aprepitant 125 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous midazolam 2 mg
Number of subjects: 12
Study: 14997286

Group type: EXPERIMENTAL
Intervention: Hip protectors (three pairs of 'shell' type)
Number of subjects: 4169

Group type: COMPARATOR
Intervention: Control group (no hip protectors)
Number of subjects: 4169

Group type: EXPERIMENTAL
Intervention: Regular use of hip protectors
Number of subjects: 4169
Study: 11104314

Group type: EXPERIMENTAL
Intervention: Combined treatment (Comb) group (medicated)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Behavioral treatment (Beh) group (unmedicated)
Number of subjects: 117
Study: 9314913

Group type: EXPERIMENTAL
Intervention: Oral micronized E2 (2 mg daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8393365

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (ara-C) as a repair inhibitor of cyclophosphamide (Cy) resistance
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 67
Study: 2873131

Group type: EXPERIMENTAL
Intervention: Alprazolam (3.67 mg)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Imipramine (167 mg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 98
Study: 30451806

Group type: EXPERIMENTAL
Intervention: BioTrue ONEday for Presbyopia
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Acuvue Moist Multifocal
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dailies AquaComfort Plus Multifocal
Number of subjects: 72
Study: 28827238

Group type: EXPERIMENTAL
Intervention: Balanced plate nutrition education with practical demonstration from community health workers 4-7 times throughout pregnancy
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard nutrition education delivered by public and other healthcare providers
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Balanced plate nutrition education
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard nutrition education
Number of subjects: 900
Study: 25909463

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention in primary care teams
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no pharmacist intervention)
Number of subjects: 200
Study: 24427663

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 26

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 26
Study: 21219391

Group type: EXPERIMENTAL
Intervention: Porcelain-fused-to-metal (PFM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: All-ceramic
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both PFM and all-ceramic
Number of subjects: 20
Study: 18502262

Group type: EXPERIMENTAL
Intervention: Fenofibrate (FENO) 160 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coadministration of FENO + EZE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17333838

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using delta‐aminolevulinic acid in a water‐in‐oil emulsion applied to lesions, repeated once a week for a month
Number of subjects: 5
Study: 12804082

Group type: EXPERIMENTAL
Intervention: Throat Coat (5-8 oz, 4-6 times daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (5-8 oz, 4-6 times daily)
Number of subjects: 60
Study: 11191784

Group type: EXPERIMENTAL
Intervention: Lifting a 15-kg weight from elbow to shoulder level
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Asymmetric lifting
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 90 degrees right lateral plane lifting
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lifting a 15-kg weight
Number of subjects: 16
Study: 9175683

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 90
Study: 1437248

Group type: EXPERIMENTAL
Intervention: Clyburn dynamic external fixator
Number of subjects: 70

Group type: COMPARATOR
Intervention: Forearm plaster
Number of subjects: 70
Study: 31839677

Group type: EXPERIMENTAL
Intervention: Docetaxel plus MEK inhibitor selumetinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30855741

Group type: EXPERIMENTAL
Intervention: Flexible duty-hour policies (maintaining an 80-hour workweek without limits on shift length or mandatory time off between shifts)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard duty-hour policies (2011 regulations)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Flexible duty-hour policies
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard duty-hour policies
Number of subjects: 398
Study: 27694160

Group type: EXPERIMENTAL
Intervention: Group-based peer support programme (24-month intervention with regular group meetings facilitated by trained peer supporters).
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group (standard disease management programme without peer support).
Number of subjects: 261
Study: 26887585

Group type: EXPERIMENTAL
Intervention: Targeting the Teachable Moment (TTMI)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Standard Lifestyle Management (SLM)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 173
Study: 24854326

Group type: EXPERIMENTAL
Intervention: Prophylactic professional oral health care (POHC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Self-care
Number of subjects: 26
Study: 21932426

Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccine (PPV)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No PPV (historical control)
Number of subjects: 42
Study: 19556637

Group type: EXPERIMENTAL
Intervention: Linex
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lacto-G
Number of subjects: 100
Study: 18555932

Group type: EXPERIMENTAL
Intervention: S(‐)‐amlodipine nicotinate 2.5 mg QD
Number of subjects: 124

Group type: COMPARATOR
Intervention: Amlodipine besylate 5 mg QD
Number of subjects: 124
Study: 16055451

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Minimal acupuncture
Number of subjects: 270

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal acupuncture
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Acupuncture vs Waiting list
Number of subjects: 270
Study: 12202014

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment
Number of subjects: 128

Group type: COMPARATOR
Intervention: 12-step treatment
Number of subjects: 128
Study: 10781211

Group type: EXPERIMENTAL
Intervention: Graftskin plus compression therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard compression therapy (active control)
Number of subjects: 120
Study: 7718369

Group type: EXPERIMENTAL
Intervention: Positive suggestion
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control (no suggestions)
Number of subjects: 226
Study: 1835704

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Vascular surgery
Number of subjects: 102
Study: 6791596

Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate (20 mg four times daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral choline theophyllinate (6.7 mg/kg four times daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31576434

Group type: EXPERIMENTAL
Intervention: Systematic prevention and treatment of fever
Number of subjects: 184

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 184
Study: 28561231

Group type: EXPERIMENTAL
Intervention: Caffeine (overt) 200 mg
Number of subjects: 32
Study: 26551771

Group type: COMPARATOR
Intervention: Salicylic acid 30% peeling
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid 25% peeling
Number of subjects: 20
Study: 23288758

Group type: EXPERIMENTAL
Intervention: Ligament balancing (LB) technique
Number of subjects: 77

Group type: COMPARATOR
Intervention: Bone referencing (BR) technique
Number of subjects: 77
Study: 21885077

Group type: EXPERIMENTAL
Intervention: Single dose of albendazole (400mg)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Single dose of mebendazole (500mg)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Combination of albendazole (400mg) and mebendazole (500mg)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Double dose of albendazole (400mg/400mg)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Double dose of mebendazole (500mg/500mg)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Combination of double doses of albendazole and mebendazole
Number of subjects: 611

Group type: COMPARATOR
Intervention: Single drugs (albendazole or mebendazole)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Combination treatment (albendazole + mebendazole)
Number of subjects: 611
Study: 19703830

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 microg + fluticasone propionate 500 microg twice daily
Number of subjects: 6112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6112

Group type: EXPERIMENTAL
Intervention: Good adherence (>80% use of study medication)
Number of subjects: 6112

Group type: COMPARATOR
Intervention: Poor adherence (<=80% use of study medication)
Number of subjects: 6112

Group type: EXPERIMENTAL
Intervention: Good adherence
Number of subjects: 6112
Study: 17854028

Group type: EXPERIMENTAL
Intervention: MYP (myeloid cell purging system) during treatment interruption
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no MYP)
Number of subjects: 12
Study: 14973305

Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg q8h with rifabutin 300 mg qd
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg q8h with rifabutin 150 mg qd
Number of subjects: 24

Group type: COMPARATOR
Intervention: Indinavir alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rifabutin alone
Number of subjects: 24
Study: 11169074

Group type: EXPERIMENTAL
Intervention: rBPI21
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9224337

Group type: EXPERIMENTAL
Intervention: Introducer tip catheter
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Introducer tip catheter in intermittent catheterization only group
Number of subjects: 4

Group type: COMPARATOR
Intervention: Non-introducer tip catheter
Number of subjects: 4
Study: 7946243

Group type: EXPERIMENTAL
Intervention: GH/hMG/hCG
Number of subjects: 26

Group type: COMPARATOR
Intervention: hMG/hCG
Number of subjects: 26
Study: 3348966

Group type: EXPERIMENTAL
Intervention: PUVA treatment for 14 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: UVA irradiation alone for 14 days
Number of subjects: 7
Study: 31802233

Group type: EXPERIMENTAL
Intervention: Needle group (20 ml of 0.5% ropivacaine via needle)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Catheter group (20 ml of 0.5% ropivacaine via catheter)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Needle group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Catheter group
Number of subjects: 34
Study: 29610272

Group type: EXPERIMENTAL
Intervention: High-AGE meal (30,000 kU AGE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-AGE meal (3,000 kU AGE)
Number of subjects: 10
Study: 28236223

Group type: EXPERIMENTAL
Intervention: Calcipotriol plus Betamethasone Dipropionate (Cal/BD) foam
Number of subjects: 159

Group type: COMPARATOR
Intervention: Gel
Number of subjects: 159
Study: 26148007

Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine followed by two doses of RTS,S/AS01 (ARR-group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Three doses of RTS,S/AS01 (RRR-group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ARR-group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Protected subjects (overall)
Number of subjects: 55
Study: 24019080

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) at 160/80/40 mg every two weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Azathioprine (AZA) at 2 mg/kg/day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Mesalamine at 3 g/day
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Mesalamine
Number of subjects: 51
Study: 21349456

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 80
Study: 17495878

Group type: EXPERIMENTAL
Intervention: Goldenseal (Hydrastis canadensis)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Kava kava (Piper methysticum)
Number of subjects: 16
Study: 16763853

Group type: EXPERIMENTAL
Intervention: Mechanical vibration (100 Hz frequency and < 20 microm amplitude) applied to the quadriceps muscle, started one month after surgery, for short periods over three consecutive days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated subjects standing on the operated leg).
Number of subjects: 0
Study: 12586799

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 284
Study: 10551572

Group type: COMPARATOR
Intervention: 8 mg bupivacaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 12 mg ropivacaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 14 mg ropivacaine
Number of subjects: 150
Study: 8678182

Group type: EXPERIMENTAL
Intervention: Enhanced outreach counseling (N = 27)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard referral condition (N = 14)
Number of subjects: 94
Study: 1830700

Group type: EXPERIMENTAL
Intervention: End-range extension movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: End-range flexion movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 6837621

Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prazosin (15 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of clonidine and prazosin
Number of subjects: 24
Study: 30080456

Group type: EXPERIMENTAL
Intervention: Simplified default amount of financial information on Plan Finder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Plan Finder tool with complex financial information
Number of subjects: 0
Study: 27062079

Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (PR) 100-250 mg bid
Number of subjects: 129

Group type: COMPARATOR
Intervention: Overall tapentadol PR group
Number of subjects: 129
Study: 25042089

Group type: EXPERIMENTAL
Intervention: Hi‐oleic peanuts
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Regular peanuts
Number of subjects: 24

Group type: COMPARATOR
Intervention: Potato crisps
Number of subjects: 24